Clinical Trial Update: A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

View source ↗

Summary

A two-year prospective observational study of Wegovy (semaglutide) in real-world clinical practice for obesity, currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• WEGOVY (Semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Obesity | Status: ENROLLING_BY_INVITATION